
Grail (GRAL) shares were cut in half on Feb. 20 after the biotech firm said its highly anticipated NHS-Galleri clinical trial failed to meet its primary endpoint.
As retail and institutional investors bailed on GRAL today, its 14-day relative strength index (RSI) crashed to 24, indicating a technical rebound was likely in the near term.